SCHEMBL2883455

SCHEMBL2883455

COc1ccc(-c2nn3cnnc3c3cccnc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
MAPT P10636 6/20 0.47
POLB P06746 2/20 0.47
ATM Q13315 2/20 0.47
MAOB P27338 4/20 0.46
HTT P42858 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
TP53 P04637 2/20 0.41
CLK4 Q9HAZ1 1/20 0.40
LMNA P02545 2/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 2/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPK1 P28482 1/20 0.39
OPRK1 P41145 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885687 0.90 ALDH1A1 (0.51) ALDH1A1MAPTPOLBATMMAOB
SCHEMBL2886124 0.84 ALDH1A1 (0.51) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL2880447 0.79 HRH3 (0.43) ALDH1A1
SCHEMBL2883504 0.78 HRH3 (0.52)
SCHEMBL2888905 0.77 ALDH1A1 (0.52) ALDH1A1MAPTPOLBATMMAOB
SCHEMBL2883462 0.77 HRH3 (0.46)
SCHEMBL2885895 0.73 ALDH1A1 (0.51) ALDH1A1MAPTHTTKMT2AMEN1
SCHEMBL2880814 0.71 ALDH1A1 (0.50) ALDH1A1MAPTATMMAOBHTT
SCHEMBL7369331 0.71 SRC (0.46) ALDH1A1MAPTMAOBKDM4EHPGD
SCHEMBL7365416 0.71 ALDH1A1 (0.50) ALDH1A1MAPTMAOBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 ALDH1A1 1934/4885MAPT 3450/4885POLB 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.